Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.55 |
| ▸ | HTR1D | P28221 | 3/20 | 0.49 |
| ▸ | HTR1B | P28222 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | HTR1E | P28566 | 1/20 | 0.49 |
| ▸ | HTR1F | P30939 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL9705330 | 0.96 | CYP19A1 (0.51) | CYP19A1HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL1275476 | 0.85 | HDAC1 (0.48) | CYP19A1HTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL8990514 | 0.82 | EPHX2 (0.53) | CYP19A1HDAC1HDAC8EPHX2PPARG | |
| SCHEMBL9275073 | 0.81 | CYP19A1 (0.47) | CYP19A1HDAC1HDAC8EPHX2PPARG | |
| SCHEMBL1650589 | 0.79 | CA1 (0.51) | CYP19A1HDAC1HDAC8EPHX2PPARG | |
| SCHEMBL30155019 | 0.79 | CA1 (0.51) | CYP19A1HDAC1HDAC8EPHX2PPARG | |
| Sulfuric Acid SCHEMBL1491064 | 0.75 | CA1 (0.48) | CYP19A1HDAC1HDAC8EPHX2PPARG | |
| SCHEMBL10753454 | 0.75 | NFATC1 (0.61) | CYP19A1HDAC1HDAC8EPHX2PPARG | |
| SCHEMBL1252143 | 0.75 | KDM1A (0.50) | HDAC1HDAC8CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL29644286 | 0.75 | KDM1A (0.50) | HDAC1HDAC8CYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090076121-A1 | DEUTERIUM-ENRICHED SUMATRIPTAN | PROTIA, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| US-20090076121-A1 | DEUTERIUM-ENRICHED SUMATRIPTAN | PROTIA, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| US-20060106227-A1 | 3-'2-(Dimethylamino) ethyl!-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof | DR REDDY'S LABORATORIES LIMITED (IN) | 2006-05-18 | — | — | US | disclosed |
| WO-2003105836-A1 | 3-'2-(Dimethylamino) ethyl!-N-methyl-1H-indole-5-methanesulfonamide and the Succinate Thereof | DR. REDDY'S LABORATORIES LIMITED (IN) | 2003-12-24 | — | — | WO | disclosed |
| US-5863559-A | 3-(2-(DIMETHYLAMINO)ETHYL)-N-METHYL-1H-INDOLE-5-METHANESULPHON AMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF IN TABLET FORM | GLAXO GROUP LIMITED (GB) | 1999-01-26 | — | — | US | disclosed |
| US-5583149-A | TREATING VASCULAR HEADACHES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5468768-A | FOR TREATING VASCULAR HEADACHES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-21 | — | — | US | disclosed |
| EP-0666258-A1 | Indolylcycloaklanylamin- und Indolylcycloalkenylamine derivatives, their preparation and their use as anti-migraine agents | Bristol-Myers Squibb Company (US) | 1995-08-09 | — | — | EP | disclosed |
| EP-0548813-A1 | Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines | Bristol-Myers Squibb Company (US) | 1993-06-30 | — | — | EP | disclosed |
| EP-0462837-A2 | Preparation of indole derivatives | GLAXO GROUP LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
| US-5037845-A | Analgesics; for treatment or prevention of pain due to vasodilation in the cranium | GLAXO GROUP LIMITED (GB) | 1991-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076121-A1 | DEUTERIUM-ENRICHED SUMATRIPTAN | SLC6A4, SLC6A3, HTR3A | CYP19A1 665/4885HTR1D 7/4885HTR1B 86/4885 |
| US-20060106227-A1 | 3-'2-(Dimethylamino) ethyl!-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof | SDHA, HTR3A, HTR5A | CYP19A1 1450/4885HTR1D 13/4885HTR1B 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.